Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2010

View Archived Issues

DHMEQ promotes allograft survival and attenuates diabetes in preclinical studies

AZ-889 shows potent antinociceptive activity in vivo

ARRY-470 shows promising analgesic activity in vivo

PET ligand [11C]-AZ-10419369 is sensitive to changes in brain serotonin levels in vivo

New GlyT-1 inhibitors identified by sanofi-aventis

GSK responds to article on rosiglitazone

Celgene claims new isotopically enriched thalidomide derivatives

Astellas presents new inhibitors of PI3K-delta and IL-2 production

AstraZeneca describes new androgen receptor ligands

Banyu Pharmaceutical discloses novel inhibitors of MGAT2

Genzyme rejects acquisition proposal from sanofi-aventis

CBio completes recruitment for phase II XToll trial in rheumatoid arthritis

Nabi enters agreement with Diosynth for manufacture of NicVAX nicotine vaccine

Addex Pharma drug candidate is efficacious in preclinical model of Alzheimer's disease

Biofrontera reports increase of capital

Stallergenes and Shionogi partner on two immunotherapy tablets

MorphoSys and Absynth collaborate on research into infectious disease

Emerald BioStructure and SomaLogic collaborate on SOMAmers and small-molecule therapeutics

NC-2500 is selected for clinical development in gout-related hyperuricemia

OvPlex ovarian cancer diagnostic is launched in Singapore

Eisai launches bendamustine in Singapore for non-Hodgkin's lymphoma and CLL

FDA will not meet PDUFA date for fentanyl citrate NDA for cancer pain

Merck & Co. provides update on progress second quarter 2010

Pevion secures funds to develop VLPs for vaccines

Scancell reports encouraging data on DNA vaccine in animal model of melanoma